Trevena Past Earnings Performance
Past criteria checks 0/6
Trevena's earnings have been declining at an average annual rate of -14%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 21.5% per year.
Key information
-14.0%
Earnings growth rate
8.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -21.5% |
| Return on equity | n/a |
| Net Margin | -1,289.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Trevena makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3 | -40 | 20 | 16 |
| 30 Sep 23 | 3 | -31 | 22 | 16 |
| 30 Jun 23 | 3 | -38 | 25 | 17 |
| 31 Mar 23 | 0 | -45 | 30 | 17 |
| 31 Dec 22 | 0 | -54 | 35 | 18 |
| 30 Sep 22 | 0 | -61 | 39 | 19 |
| 30 Jun 22 | 0 | -59 | 42 | 17 |
| 31 Mar 22 | 0 | -58 | 42 | 16 |
| 31 Dec 21 | 1 | -52 | 38 | 13 |
| 30 Sep 21 | 1 | -50 | 37 | 13 |
| 30 Jun 21 | 3 | -41 | 30 | 14 |
| 31 Mar 21 | 3 | -33 | 23 | 14 |
| 31 Dec 20 | 3 | -29 | 19 | 13 |
| 30 Sep 20 | 3 | -24 | 15 | 12 |
| 30 Jun 20 | 0 | -27 | 14 | 14 |
| 31 Mar 20 | 0 | -25 | 14 | 13 |
| 31 Dec 19 | 0 | -25 | 13 | 13 |
| 30 Sep 19 | 0 | -26 | 13 | 13 |
| 30 Jun 19 | 3 | -22 | 14 | 11 |
| 31 Mar 19 | 6 | -27 | 17 | 13 |
| 31 Dec 18 | 6 | -31 | 19 | 16 |
| 30 Sep 18 | 6 | -38 | 21 | 20 |
| 30 Jun 18 | 3 | -49 | 22 | 59 |
| 31 Mar 18 | 0 | -60 | 20 | 54 |
| 31 Dec 17 | 0 | -72 | 20 | 49 |
| 30 Sep 17 | 0 | -93 | 19 | 42 |
| 30 Jun 17 | 0 | -107 | 18 | 0 |
| 31 Mar 17 | 2 | -106 | 17 | 0 |
| 31 Dec 16 | 4 | -103 | 16 | 90 |
| 30 Sep 16 | 6 | -82 | 16 | 0 |
| 30 Jun 16 | 8 | -63 | 14 | 0 |
| 31 Mar 16 | 8 | -55 | 14 | 0 |
| 31 Dec 15 | 6 | -51 | 13 | 0 |
| 30 Sep 15 | 4 | -48 | 11 | 0 |
| 30 Jun 15 | 3 | -53 | 11 | 0 |
| 31 Mar 15 | 1 | -53 | 10 | 0 |
| 31 Dec 14 | 0 | -50 | 9 | 0 |
| 30 Sep 14 | 0 | -43 | 9 | 0 |
| 30 Jun 14 | 0 | -37 | 8 | 0 |
| 31 Mar 14 | 0 | -30 | 6 | 0 |
| 31 Dec 13 | 0 | -24 | 5 | 0 |
| 30 Sep 13 | 0 | -20 | 3 | 0 |
| 30 Jun 13 | 1 | -15 | 3 | 0 |
Quality Earnings: 6T40 is currently unprofitable.
Growing Profit Margin: 6T40 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6T40 is unprofitable, and losses have increased over the past 5 years at a rate of 14% per year.
Accelerating Growth: Unable to compare 6T40's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6T40 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 6T40's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.